Time for AbbVie to sharpen its pencil a fourth time

|By:, SA News Editor

Borrowing a page from AstraZeneca's (AZN) playbook, Shire plc (SHPG) publishes its "Path to US$10B In Product Sales by 2020" as a clear message to AbbVie (ABBV) that it needs to substantially increase its offer if it wants the BOD to seriously consider it.

Shire emphasizes its accelerating top-line growth, enhanced profitability, rich pipeline and total shareholder returns as proof that current management is on the right track and that Shire's future is bright continuing as an independent company.